Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Muscarinic Antagonists | 5 | 2019 | 176 | 2.14 | Why? |
| Adrenergic beta-2 Receptor Agonists | 5 | 2019 | 142 | 2.13 | Why? |
| Pulmonary Disease, Chronic Obstructive | 15 | 2019 | 3832 | 1.81 | Why? |
| Bronchodilator Agents | 5 | 2019 | 444 | 1.56 | Why? |
| Tuberous Sclerosis | 2 | 2018 | 63 | 0.86 | Why? |
| Inspiratory Capacity | 2 | 2018 | 47 | 0.74 | Why? |
| Indans | 1 | 2018 | 54 | 0.73 | Why? |
| Glycopyrrolate | 1 | 2018 | 51 | 0.71 | Why? |
| Spirometry | 3 | 2018 | 524 | 0.69 | Why? |
| Tropanes | 1 | 2017 | 18 | 0.69 | Why? |
| Liver Cirrhosis, Biliary | 1 | 2017 | 42 | 0.68 | Why? |
| Lymphangioleiomyomatosis | 1 | 2017 | 39 | 0.67 | Why? |
| Formoterol Fumarate | 2 | 2017 | 61 | 0.66 | Why? |
| Quinolones | 1 | 2018 | 167 | 0.65 | Why? |
| Exercise Tolerance | 2 | 2021 | 634 | 0.63 | Why? |
| Sarcoidosis, Pulmonary | 1 | 2017 | 91 | 0.62 | Why? |
| Respiratory Function Tests | 5 | 2021 | 1755 | 0.59 | Why? |
| Early Medical Intervention | 1 | 2019 | 487 | 0.58 | Why? |
| Adrenal Cortex Hormones | 4 | 2019 | 6537 | 0.54 | Why? |
| Hepatitis, Autoimmune | 1 | 2017 | 254 | 0.50 | Why? |
| Forced Expiratory Volume | 5 | 2018 | 632 | 0.46 | Why? |
| Vital Capacity | 4 | 2017 | 399 | 0.45 | Why? |
| Exercise Test | 2 | 2021 | 911 | 0.45 | Why? |
| Smokers | 1 | 2017 | 550 | 0.44 | Why? |
| General Practitioners | 1 | 2017 | 568 | 0.41 | Why? |
| Serum Amyloid P-Component | 2 | 2021 | 193 | 0.38 | Why? |
| Drug Therapy, Combination | 3 | 2021 | 7268 | 0.33 | Why? |
| Drug Combinations | 5 | 2019 | 3852 | 0.30 | Why? |
| Administration, Inhalation | 5 | 2019 | 1647 | 0.30 | Why? |
| Bronchoscopy | 3 | 2020 | 991 | 0.25 | Why? |
| Asthma | 3 | 2018 | 4383 | 0.23 | Why? |
| Lung Neoplasms | 3 | 2018 | 3228 | 0.23 | Why? |
| Complement Pathway, Mannose-Binding Lectin | 1 | 2020 | 44 | 0.21 | Why? |
| Vascular Resistance | 1 | 2020 | 148 | 0.20 | Why? |
| Vasoconstriction | 1 | 2020 | 153 | 0.19 | Why? |
| Obesity Hypoventilation Syndrome | 1 | 2018 | 20 | 0.19 | Why? |
| Dabigatran | 1 | 2021 | 204 | 0.19 | Why? |
| Exercise | 2 | 2021 | 6771 | 0.18 | Why? |
| Expert Systems | 1 | 2018 | 42 | 0.18 | Why? |
| Software Design | 1 | 2018 | 87 | 0.18 | Why? |
| Transition to Adult Care | 1 | 2018 | 56 | 0.18 | Why? |
| Chest Wall Oscillation | 1 | 2017 | 17 | 0.18 | Why? |
| Plethysmography, Whole Body | 1 | 2017 | 33 | 0.17 | Why? |
| Lung Diseases | 4 | 2020 | 2361 | 0.17 | Why? |
| Italy | 14 | 2021 | 38444 | 0.17 | Why? |
| Hyperplasia | 1 | 2017 | 204 | 0.16 | Why? |
| Nitrogen | 1 | 2017 | 106 | 0.16 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.16 | Why? |
| Warfarin | 1 | 2021 | 402 | 0.16 | Why? |
| Thrombotic Microangiopathies | 1 | 2020 | 335 | 0.16 | Why? |
| Ultrasonography, Doppler, Transcranial | 1 | 2017 | 143 | 0.16 | Why? |
| C-Reactive Protein | 3 | 2021 | 7972 | 0.15 | Why? |
| Carbon Monoxide | 1 | 2017 | 167 | 0.15 | Why? |
| Posture | 1 | 2017 | 199 | 0.15 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.15 | Why? |
| Hemoptysis | 1 | 2018 | 172 | 0.15 | Why? |
| Interleukin-8 | 1 | 2021 | 964 | 0.14 | Why? |
| Electromyography | 1 | 2016 | 278 | 0.14 | Why? |
| Disease Progression | 4 | 2017 | 13580 | 0.14 | Why? |
| Foramen Ovale, Patent | 1 | 2017 | 153 | 0.14 | Why? |
| Embolization, Therapeutic | 1 | 2018 | 269 | 0.14 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.14 | Why? |
| Drug Therapy | 1 | 2017 | 280 | 0.14 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.13 | Why? |
| Awareness | 1 | 2018 | 529 | 0.13 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.13 | Why? |
| Early Diagnosis | 2 | 2020 | 2443 | 0.13 | Why? |
| Specialization | 1 | 2017 | 432 | 0.12 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.12 | Why? |
| Hemodynamics | 1 | 2020 | 1562 | 0.12 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.12 | Why? |
| Quality of Life | 3 | 2017 | 9820 | 0.11 | Why? |
| Pulmonary Medicine | 1 | 2018 | 706 | 0.11 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.11 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.11 | Why? |
| Noninvasive Ventilation | 3 | 2021 | 2329 | 0.11 | Why? |
| Hypertension, Pulmonary | 1 | 2020 | 970 | 0.11 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2017 | 398 | 0.11 | Why? |
| Hypoxia | 3 | 2021 | 3626 | 0.11 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.11 | Why? |
| Ultrasonography | 2 | 2017 | 4409 | 0.11 | Why? |
| Humans | 42 | 2021 | 930598 | 0.10 | Why? |
| Middle Aged | 21 | 2021 | 270681 | 0.10 | Why? |
| Emergency Medicine | 1 | 2020 | 936 | 0.10 | Why? |
| Alveolar Epithelial Cells | 1 | 2017 | 1445 | 0.10 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.09 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.09 | Why? |
| Smoking Cessation | 1 | 2017 | 826 | 0.09 | Why? |
| Ventilators, Mechanical | 1 | 2021 | 2193 | 0.09 | Why? |
| Macrophages | 1 | 2020 | 2784 | 0.09 | Why? |
| Evidence-Based Medicine | 2 | 2019 | 3228 | 0.09 | Why? |
| Lung | 6 | 2021 | 31049 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Treatment Outcome | 4 | 2019 | 51732 | 0.09 | Why? |
| Smoking | 2 | 2021 | 3358 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Echocardiography | 2 | 2020 | 3661 | 0.08 | Why? |
| Female | 19 | 2021 | 380317 | 0.08 | Why? |
| Scopolamine Derivatives | 1 | 2005 | 10 | 0.08 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.08 | Why? |
| Male | 20 | 2021 | 367725 | 0.08 | Why? |
| Ethanolamines | 1 | 2005 | 71 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| Aged | 14 | 2021 | 215776 | 0.07 | Why? |
| Sex Factors | 2 | 2021 | 11014 | 0.07 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.07 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.07 | Why? |
| Budesonide | 1 | 2005 | 192 | 0.06 | Why? |
| Oxygen | 1 | 2017 | 3715 | 0.06 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.06 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.06 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Oxygen Inhalation Therapy | 1 | 2016 | 3629 | 0.06 | Why? |
| Glucocorticoids | 2 | 2017 | 4431 | 0.06 | Why? |
| Withholding Treatment | 2 | 2019 | 798 | 0.06 | Why? |
| Acute Disease | 3 | 2021 | 6029 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2017 | 4927 | 0.06 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.06 | Why? |
| Mannose-Binding Protein-Associated Serine Proteases | 1 | 2020 | 41 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.05 | Why? |
| Ventilation-Perfusion Ratio | 1 | 2020 | 99 | 0.05 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Cardiac Output | 1 | 2020 | 183 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Lung Compliance | 1 | 2020 | 243 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Thoracentesis | 1 | 2018 | 23 | 0.05 | Why? |
| Illness Behavior | 1 | 2018 | 76 | 0.05 | Why? |
| X-Rays | 1 | 2020 | 492 | 0.04 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.04 | Why? |
| Thoracoscopy | 1 | 2018 | 113 | 0.04 | Why? |
| Pleural Diseases | 1 | 2018 | 68 | 0.04 | Why? |
| Decision Trees | 1 | 2019 | 441 | 0.04 | Why? |
| Severity of Illness Index | 6 | 2021 | 48226 | 0.04 | Why? |
| Prognosis | 2 | 2020 | 32490 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Respiratory Insufficiency | 1 | 2018 | 7301 | 0.04 | Why? |
| Tomography, X-Ray Computed | 3 | 2021 | 25144 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Bronchitis | 1 | 2018 | 146 | 0.04 | Why? |
| Oxygen Consumption | 1 | 2021 | 711 | 0.04 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Respiratory Muscles | 1 | 2016 | 116 | 0.04 | Why? |
| A549 Cells | 1 | 2020 | 2066 | 0.03 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2021 | 830 | 0.03 | Why? |
| Tidal Volume | 1 | 2017 | 565 | 0.03 | Why? |
| Administration, Oral | 1 | 2021 | 2340 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2020 | 882 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Hygiene | 1 | 2020 | 987 | 0.03 | Why? |
| Critical Care | 1 | 2016 | 14081 | 0.03 | Why? |
| Patient Discharge | 2 | 2021 | 5696 | 0.03 | Why? |
| Intellectual Disability | 1 | 2018 | 391 | 0.03 | Why? |
| Continuous Positive Airway Pressure | 1 | 2021 | 1187 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Cell Line, Tumor | 1 | 2020 | 3608 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Airway Extubation | 1 | 2016 | 403 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2021 | 4260 | 0.03 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.03 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.03 | Why? |
| Cannula | 1 | 2016 | 750 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.03 | Why? |
| Recovery of Function | 1 | 2021 | 2461 | 0.03 | Why? |
| Recurrence | 1 | 2021 | 3675 | 0.03 | Why? |
| Bronchi | 1 | 2018 | 1048 | 0.03 | Why? |
| Nose | 1 | 2016 | 1093 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2018 | 1425 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.03 | Why? |
| Endothelial Cells | 1 | 2020 | 2048 | 0.03 | Why? |
| Cells, Cultured | 1 | 2020 | 5835 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Poland | 1 | 2017 | 2368 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2018 | 10649 | 0.02 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.02 | Why? |
| Monocytes | 1 | 2020 | 2978 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.02 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.02 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Epilepsy | 1 | 2018 | 1401 | 0.02 | Why? |
| Tiotropium Bromide | 1 | 2005 | 46 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Mobile Applications | 1 | 2021 | 3032 | 0.02 | Why? |
| Myocardial Infarction | 1 | 2021 | 3361 | 0.02 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.02 | Why? |
| Cough | 1 | 2018 | 4891 | 0.02 | Why? |
| Neutrophils | 1 | 2020 | 5476 | 0.02 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.01 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Spain | 1 | 2017 | 15545 | 0.01 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.01 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.01 | Why? |
| Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
| Double-Blind Method | 1 | 2005 | 5988 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |